Ian Somaiya

In reports published on Monday, Wells Fargo analyst Matthew Andrews and Piper Jaffray analyst Ian Somaiya had mixed responses on Infinity Pharma (NASDAQ: INFI) CLL drug data. Wells Fargo calls the data "Very Solid" as its Phase 1/2 data on IPI-145 in chronic lymphocytic leukemia (CLL)...